Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

BACKGROUND: Sunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma (MRCC) setting at the dose of 50 mg daily for 4 weeks followed by a pause of 2 weeks. Due to toxicity, this standard schedule (50 mg daily 4/2) can induce up to 50% of sunitinib dose modif...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trials
Main Authors: Mouillet, Guillaume, Paillard, Marie-Justine, Maurina, Tristan, Vernerey, Dewi, Nguyen Tan Hon, Thierry, Almotlak, Hamadi, Stein, Ulrich, Calcagno, Fabien, Berthod, Diane, Robert, Elise, Meurisse, Aurelia, Thiery-Vuillemin, Antoine
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5898055/
https://ncbi.nlm.nih.gov/pubmed/29650037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-018-2613-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados